Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
Ajay Nooka, MD, explains how he selects treatment regimens for patients with newly diagnosed transplant-eligible multiple myeloma in his clinical practice.
EP: 1.Frontline Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 2.Comparison of Results from the MAIA and SWOG0777 Studies
EP: 3.Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
EP: 4.Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
EP: 5.Maintenance Therapy in Transplant-Ineligible Multiple Myeloma
EP: 6.Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
EP: 7.Unmet Needs of Transplant-Ineligible Multiple Myeloma
EP: 8.Racial Disparities in the Treatment of Multiple Myeloma Patients
EP: 9.Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
EP: 10.Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
EP: 11.The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
Now Viewing
EP: 12.Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
EP: 13.Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
EP: 14.Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
EP: 15.Recap: Recent Advances in Multiple Myeloma: Applying Real-world Evidence to Clinical Practice
EP: 16.Determining Treatment Duration for Transplant-Eligible NDMM
EP: 17.Racial Disparities in Presentation, Diagnosis, and Treatment of MM
EP: 18.Unmet Needs and Future Perspectives in Transplant-Eligible NDMM
EP: 19.Characterization and Management of High-Risk Patients with MM
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
